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We here describe two proteomic datasets deposited in Proteo-
meXchange via PRIDE partner repository [1] with dataset identiﬁers
PXD000484 (deﬁned as “training”) and PXD000485 (deﬁned as “test”)
that have been used for the development of a tamoxifen outcome
predictive signature [2]. Both datasets comprised 56 fresh frozen
estrogen receptor (ER) positive primary breast tumor specimens
derived from patients who received tamoxifen as ﬁrst line therapy for
recurrent disease. Patient groups were deﬁned based on time to pro-
gression (TTP) after start of tamoxifen therapy (6 months cutoff): 32
good and 24 poor treatment outcome patients were comprised in the
training set, respectively. The test set included 41 good and 15 poor
treatment outcome patients. All specimens were subjected to laser
capture microdissection (LCM) to enrich for epithelial tumor cells prior
to high resolution mass spectrometric (MS) analysis. Protein identiﬁ-
cation and label-free quantiﬁcation (LFQ) were performed with Max-
Quant software package [3]. A total of 3109 and 4061 proteins were
identiﬁed and quantiﬁed in the training and test set, respectively. We
here present the ﬁrst public proteomic dataset analyzing ER positive
recurrent breast cancer by LCM coupled to high resolution MS.
& 2015 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).vier Inc. This is an open access article under the CC BY license
e Marchi).
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DSubject area Biologyore speciﬁc sub-
ject areaClinical Proteomicsype of data 1. RAW MS Orbitrap XL data
2. MaxQuant “Protein groups.txt” outputow data was
acquiredLTQ Orbitrap XL MS interfaced with a reverse phase column (PepMap C18, 75 mm
ID x 50 cm, 3 mm particle size, 100
Â
e pore size).ata format RAW;.txt
xperimental
factorsAll ER positive fresh frozen breast cancer tissues were subjected to LCM to enrich
for epithelial tumor cells prior to protein digestion, which enabled analysis of
highly pure subpopulations of breast cancer cells.xperimental
features1. Cryo-sectioning of breast cancer tissues and collection on polyethylene–naph-
talate coated slides
2. Hematoxylin staining and LCM-enrichment
3. Protein digestion (MS Grade Trypsin)
4. LC–MS analysis
5. Label-free quantitation (LFQ) by MaxQuant softwareata source
locationRotterdam, The Netherlandsata accessibility PXD000484:http://proteomecentral.proteomexchange.org/cgi/GetDataset?
ID¼PXD000484
PXD000485:http://proteomecentral.proteomexchange.org/cgi/GetDataset?
ID¼PXD000485Value of the data First public proteomics datasets of LCM derived ER positive primary tumor cells analyzed by high
resolution MS.
 Characterization of proteomic changes related to resistance to ﬁrst line tamoxifen therapy.
 Quantiﬁcation of 3109 and 4061 unique proteins in training and test sets, respectively.1. Materials and methods
1.1. Sample sets
We collected a total of 112 fresh frozen ER positive breast cancer tissues that displayed a minimum
( Z) of 40% tumor area and that were collected from patients who received tamoxifen therapy for
recurrent disease and no adjuvant hormonal therapy after resection of the primary tumor. Patient
groups were deﬁned based on outcome to tamoxifen therapy for recurrent disease: patients who
manifested progression of disease within (r) 6 months after start of therapy were deﬁned as
manifesting poor outcome, while the good outcome group comprised patients with disease pro-
gression after (4) 6 months. Patient samples in the training set (PXD000484) were collected from
Erasmus Medical Center (n¼56; 32 good, 24poor), while the test set (PXD000485) comprised
tumors collected from the Netherlands Cancer Institute – Antoni van Leeuwenhoek hospital (n¼41)
and Radboud University Medical Center (n¼15), which comprised 41 good and 15 poor outcome
T. De Marchi et al. / Data in Brief 5 (2015) 399–402 401patients, respectively, as previously reported (Ref. [2]). Clinical information for every patient in the
training an test sets are reported in Tables S1 and S2, respectively.1.2. Sample preparation
Breast cancer tissue samples were processed according to our previously reported tissue pro-
teomic workﬂow [4,5]. Frozen tissue specimens were cut into 8 mm cryo-sections, collected on
polyethylene naphtalate coated glass slides, and stained with hematoxylin. From each sample, around
4000 epithelial tumor cells were collected through LCM (corresponding to an area of 500,000 mm2)
and suspended into 20 ml of 0.1% w/v Rapigest/50 mM ammonium bicarbonate solution.1.3. Protein digestion
LCM collected tissues were lysed through sonication at 70% amplitude. Proteins were denatured at
95 °C, reduced with a 100 mM dithiothreithol solution, and alkylated with a 300 mM iodoacetamide
solution. MS grade trypsin was added in a 1:4 enzyme–protein ratio and incubated for 4 h at 37 °C.
Digested samples were then acidiﬁed with triﬂuoroacetic acid and spun down at 14,000 RPM.
Supernatants were collected and transferred to HPLC vials for further MS measurement.1.4. High resolution MS analysis
MS measurements were performed as previously described with on an LTQ Orbitrap XL interfaced
with a nano liquid chromatography system (Ultimate 3000, Dionex, Amsterdam, The Netherlands)
[2,5,6]. Digested proteins were separated on a reverse phase analytical column (PepMap C18, 75 μm
ID50 cm, 3 μm particle size and 100 Å pore size) in a 3 h gradient: 2 h 0–25% mobile phase B (80%
acetonitrile and 0.08% formic acid), and 1 h 25–50% mobile phases B and A (2% acetonitrile and 0.1%
formic acid in puriﬁed water). The top 5 most intense peaks in full scan (from 400 to 1800 Th) were
fragmented by collision induced dissociation.1.5. Protein identiﬁcation and quantitation
Orbitrap.RAW ﬁles were analyzed by MaxQuant (v1.2.2.5), using Andromeda for peptide search
[3,7]. UniProt-SwissProt human canonical database (version 2012-09, human canonical proteome;
20,243 identiﬁers) was used as reference database. For identiﬁcation, peptide length was set to
7 aminoacids, match between runs was enabled and settings were kept as default. All other settings
were set as default. “Protein groups.txt” ﬁles were uploaded in ProteomeXchange along with Orbi-
trap.RAW ﬁles.Financial support
This study was supported by the Dutch Cancer Society (KWF), EMCR2009-4319 and the CTMM-
Breast Care project 030-104-06.Appendix A. Supplementary material
Supplementary data associated with this article can be found in the online version at http://dx.doi.
org/10.1016/j.dib.2015.09.034.
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